ClinicalTrials.gg
CompletedNCT05160415ARCHUpdated Jun 24, 2025Results posted

A Study of EDG-5506 in Adult Males With Becker Muscular Dystrophy

A Phase 1 interventional study of Sevasemten in Becker Muscular Dystrophy, sponsored by Edgewise Therapeutics, Inc.. Completed at 1 site in United States. Open to male participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2025-06-24.

Sponsored by Edgewise Therapeutics, Inc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 232 studies in Muscular Dystrophy, Duchenne with a site in United States — 34 open to participants now, 60 under way, 8 of them phase 3. Muscular Dystrophy, Duchenne · United States.

Enrollment
126th of 171
12 · median 25
Started
2021
with 11 others
Phase 1
32 of 232
3 open now
Registered
175th of 232
by date
Lead sponsor
6 of 232
Edgewise Therapeutics, Inc.

Among the 232 studies in Muscular Dystrophy, Duchenne with a site in United States, this one is the 126th largest by enrollment of the 171 interventional ones that give a count, is one of 12 that started in 2021, is one of 32 in phase 1, and was the 175th registered.

Muscular Dystrophy, Duchenne

481 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 106 are open to participants now.

Browse Muscular Dystrophy, Duchenne studies →

Open to participants now

34 of the 232 studies in Muscular Dystrophy, Duchenne with a site in United States are open now. Recruiting first, the newest first:

29 more — sign in →

All 34 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 65 Muscular Dystrophy, Duchenne studies recruiting now, 30 (46%) set no upper age limit and 33 (51%) stop at 75 or younger; 58 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 55 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 232 studies in Muscular Dystrophy, Duchenne with a site in United States, or all of them as a file.
02

Study summary

The ARCH study was an open-label, single-center, Phase 1b study of sevasemtem (EDG-5506) to assess the safety and pharmacokinetics (PK) of sevasemten in adults with Becker muscular dystrophy (BMD).

Sevasemten is an investigational product intended to protect and improve function of dystrophic muscle fibers.

Read the detailed description

This open-label study evaluated the safety, tolerability, and pharmacokinetics (PK) of sevasemten in participants with BMD who completed the first-in-human study, EDG-5506-001, as well as additional (treatment-naïve) participants from outside the EDG-5506-001 study to meet the target sample size.

All participants received sevasemten. This study had a 24 month treatment period, followed by an optional 4 week follow-up period. On-site visits occurred approximately monthly for the first 12 months, followed by every 3 months to assess safety and measures of function.

03

Conditions studied

  • Becker Muscular Dystrophy

Keywords

  • Becker Muscular Dystrophy
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants who have completed Study EDG-5506-001.
  2. Participants who were not from Study EDG-5506-001 must meet the following:

    1. Male sex at birth and aged 18 to 55 years inclusive at time of consent.
    2. Documented dystrophin mutation with phenotype consistent with BMD.
    3. Ambulatory at Screening (defined as ability to complete 100 meter [m] timed test, with or without assistance).
    4. Body weight ≥ 50 kg at the Screening visit.
    5. (BMI) between 20 and 34 kg/m2 inclusive.
  3. Female sexual partners of male participants must use highly effective (\<1% failure rate per year) through 6 months after last dose.
  4. Capable of giving signed .

Exclusion criteria

Exclusion Criteria:

  1. Any changes during or following the completion of Study EDG 5506-001 that would affect the potential safety of the participant to receive EDG 5506.
  2. Cardiac echocardiogram \<45% or (NYHA) Class III or Class IV.
  3. Baseline 12-lead (ECG) that demonstrates clinically relevant abnormalities that may affect participant safety or interpretation of study results.
  4. Forced vital capacity (FVC) predicted \<65% or using daytime (mechanical or noninvasive) ventilatory support.
  5. Moderate or severe renal or hepatic impairment ( \<60 mL/min/1.73 m2).
  6. Positive test for antibody (unless negative HCV PCR), surface antigen, or (HIV) antibody at screening.
  7. History of substance abuse or dependency.
  8. Receipt of oral for >5 days in the previous 6 months at a dose of >5 mg equivalent per day. Lower oral doses or inhaled/intranasal steroids are permitted.
  9. Receiving moderate or strong cytochrome P450 inhibitors or inducers.
  10. Participation in any other drug study or use of use of an investigational drug within 30 days or 5 half-lives (whichever is longer) of dosing in the present study.
  11. Participants who are unlikely to comply with the study protocol or, in the opinion of the Investigator, would not be a suitable candidate for participation in the study.
  12. Medical history or other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory result or abnormality that may increase the risk of study participation or, in the Investigator's judgment, make the participant inappropriate for the study. Includes venous access that would be too difficult to facilitate repeated blood sampling.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Treatment

    Drug: Sevasemten

    Drug: Sevasemten

Interventions

  • Daily oral dose of 10 mg daily until Visit 8 (Day 57), followed by 15 mg daily until Visit 13 (Month 6), followed by 20 mg until Visit 21 (Month 15), followed by 10 mg daily to Visit 27 (Month 24).

    Also known as: EDG-5506

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Treated With Sevasemten Experiencing AEs

    An AE is any untoward medical occurrence in a patient administered a medicinal product. The AE does not necessarily have to have a causal relationship with the study drug. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. The numerator of the percentage is the number of participants experiencing at least one AE after first dose of study drug up to 25 months.

    Time frame: From first dose of study drug to 25 months

  2. Frequency of AEs in Those Treated With Sevasemten

    An AE is any untoward medical occurrence in a patient administered a medicinal product. The AE does not necessarily have to have a causal relationship with the study drug. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. The endpoint is the cumulative total number of AEs occurring after first dose of study drug up to 25 months among participants who received at least one dose of study drug.

    Time frame: From first dose of study drug to 25 months

  3. Number of Participants Treated With Sevasemten With AEs by Maximum Severity

    An AE is any untoward medical occurrence in a patient administered a medicinal product. The AE does not necessarily have to have a causal relationship with the study drug. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. The severity of an AE is graded, according to the study protocol definitions of AE severity/intensity, as "mild", "moderate" or "severe". Participants who reported multiple AEs are counted only once at the highest severity reported.

    Time frame: From first dose of study drug to 25 months

Secondary outcomes

  1. Percentage of Participants Experiencing Treatment-Emergent Abnormal Clinical Chemistry Test Results

    Treatment-emergent defined as any event that occurs after the start of study drug or was present at baseline and worsened after taking study drug. The numerator of the percentage is the number of participants experiencing at least one treatment-emergent abnormal clinical chemistry test result after first dose of study drug up to 25 months.

    Time frame: From first dose of study drug to 25 months

  2. Percentage of Participants Experiencing Treatment-Emergent Abnormal Hematology Test Results

    Treatment-emergent defined as any event that occurs after the start of study drug or was present at baseline and worsened after taking study drug. The numerator of the percentage is the number of participants experiencing at least one treatment-emergent abnormal hematology test result after first dose of study drug up to 25 months.

    Time frame: From first dose of study drug to 25 months

  3. Percentage of Participants Experiencing Treatment-Emergent Abnormal Coagulation Test Results

    Treatment-emergent defined as any event that occurs after the start of study drug or was present at baseline and worsened after taking study drug. The numerator of the percentage is the number of participants experiencing at least one treatment-emergent abnormal coagulation test result after first dose of study drug up to 25 months.

    Time frame: From first dose of study drug to 25 months

  4. Percentage of Participants Experiencing Treatment-Emergent Abnormal Urinalysis Test Results

    Treatment-emergent defined as any event that occurs after the start of study drug or was present at baseline and worsened after taking study drug. The numerator of the percentage is the number of participants experiencing at least one treatment-emergent abnormal urinalysis test result after first dose of study drug up to 25 months.

    Time frame: From first dose of study drug to 25 months

  5. Number of Participants With Clinically Significant Changes in Clinical Chemistry

    Refer to Protocol for list of clinical chemistry tests that were performed. Clinically significant changes in clinical chemistry are defined as adverse events related to clinical chemistry tests or investigator identified results reported from first dose of study drug up to 24 months. Only clinically significant changes were counted.

    Time frame: From first dose of study drug to 24 months

  6. Number of Participants With Clinically Significant Changes in Hematology

    Refer to Protocol for list of hematology tests that were performed. Clinically significant changes in hematology are defined as adverse events related to hematology tests or investigator identified results reported from first dose of study drug up to 24 months. Only clinically significant changes were counted.

    Time frame: From first dose of study drug to 24 months

  7. Number of Participants With Clinically Significant Changes in Coagulation

    Refer to Protocol for list of coagulation tests that were performed. Clinically significant changes in coagulation are defined as adverse events related to coagulation tests or investigator identified results reported from first dose of study drug up to 24 months. Only clinically significant changes were counted.

    Time frame: From first dose of study drug to 24 months

  8. Number of Participants With Clinically Significant Changes in Urinalysis

    Refer to Protocol for list of urinalysis tests that were performed. Clinically significant changes in urinalysis are defined as adverse events related to urinalysis tests or investigator identified results reported from first dose of study drug up to 24 months. Only clinically significant changes were counted.

    Time frame: From first dose of study drug to 24 months

  9. Number of Participants With Clinically Significant Changes in Vital Signs

    Supine systolic and diastolic blood pressure, pulse rate, respiratory rate, and temperature were measured. Clinically significant changes in vital signs are defined as adverse events related to vital signs or investigator identified results reported from first dose of study drug up to 24 months. Only clinically significant changes were counted.

    Time frame: From first dose of study drug to 24 months

  10. Number of Participants With Clinically Significant Changes in Physical and Neurological Examinations

    A physical examination included head, ears, eyes, nose, mouth, skin, heart and lung, lymph nodes, and gastrointestinal and musculoskeletal systems. A neurological examination was also conducted to include upper and lower limb tone, power, reflexes, and examination of cranial nerves II-XII (excluding ophthalmoscopy). Clinically significant changes in physical and neurological examinations are defined as adverse events related to physical and neurological examinations or investigator identified results reported from first dose of study drug up to 24 months. Only clinically significant changes were counted.

    Time frame: From first dose of study drug to 24 months

  11. Number of Participants With Clinically Significant Changes in ECG PR Interval

    Triplicate 12-lead electrocardiogram (ECG) parameters were obtained using an ECG machine that automatically measured PR interval. Clinically significant changes in ECG PR interval are defined as adverse events related to ECG PR interval or investigator identified results reported from first dose of study drug up to 24 months. Only clinically significant changes were counted.

    Time frame: From first dose of study drug to 24 months

  12. Number of Participants With Clinically Significant Changes in ECG QRS Interval

    Triplicate 12-lead electrocardiogram (ECG) parameters were obtained using an ECG machine that automatically measured QRS interval. Clinically significant changes in ECG QRS interval are defined as adverse events related to ECG QRS interval or investigator identified results reported from first dose of study drug up to 24 months. Only clinically significant changes were counted.

    Time frame: From first dose of study drug to 24 months

  13. Number of Participants With Clinically Significant Changes in ECG QT Interval

    Triplicate 12-lead electrocardiogram (ECG) parameters were obtained using an ECG machine that automatically measured QT interval. Clinically significant changes in ECG QT interval are defined as adverse events related to ECG QT interval or investigator identified results reported from first dose of study drug up to 24 months. Only clinically significant changes were counted.

    Time frame: From first dose of study drug to 24 months

  14. Number of Participants With Clinically Significant Changes in ECG QTc Interval

    Triplicate 12-lead electrocardiogram (ECG) parameters were obtained using an ECG machine that automatically measured QT corrected (QTc) Interval. QT corrected by Bazett's formula (QTcB) and QT corrected by Fridericia's formula (QTcF) were both recorded. Clinically significant changes in ECG QTc interval are defined as adverse events related to ECG QTc interval or investigator identified results reported from first dose of study drug up to 24 months. Only clinically significant changes were counted.

    Time frame: From first dose of study drug to 24 months

  15. Number of Participants With Clinically Significant Changes in Forced Vital Capacity (FVC)

    Assessed by spirometry. Clinically significant changes in FVC are defined as adverse events related to FVC or investigator identified results reported from first dose of study drug up to 24 months. Only clinically significant changes were counted.

    Time frame: From first dose of study drug to 24 months

  16. Number of Participants With Clinically Significant Changes in Forced Expiratory Volume in 1 Second (FEV1)

    Assessed by spirometry. Clinically significant changes in FEV1 are defined as adverse events related to FEV1 or investigator identified results reported from first dose of study drug up to 24 months. Only clinically significant changes were counted.

    Time frame: From first dose of study drug to 24 months

  17. Number of Participants With Clinically Significant Changes in Cardiac Function as Assessed by Echocardiogram

    Echocardiographic examinations were performed by a qualified individual (sonographer) at the site to evaluate left-ventricular systolic and diastolic function, geometry, and mass, as well as left-atrial and right-ventricular function and geometry via two-dimensional, doppler, and/or speckle-tracking imaging techniques. Valvular competence, including presence or absence of regurgitation, was evaluated and quantified, while overall cardiac health was qualitatively evaluated (e.g., presence/absence of pericardiac effusion). Clinically significant changes in cardiac function are defined as adverse events related to cardiac function as assessed by echocardiogram or investigator identified results reported from first dose of study drug up to 24 months. Only clinically significant changes were counted.

    Time frame: From first dose of study drug to 24 months

  18. Number of Participants With Clinically Significant Changes in Columbia Suicide Severity Rating Scale (C-SSRS)

    The C-SSRS is a questionnaire used for suicide assessment. The assessment includes "yes" or "no" responses for 6 questions. Questions 1-5 are related to suicidal ideation, including: 1=Wish to be Dead, 2=Non-specific Active Suicidal Thoughts, 3=Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act, 4=Active Suicidal Ideation with Some Intent to Act, without Specific Plan, 5=Active Suicidal Ideation with Specific Plan and Intent. Question 6 is related to suicidal behavior and asks about actual attempts. Numeric ratings were provided for severity of ideation (if present), from 1 to 5, with 5 being the most severe. For this study, clinically significant changes in C-SSRS are defined as responses of "yes" to suicidal ideation or suicidal behavior item as measured by C-SSRS or investigator identified results reported from first dose of study drug to 24 months.

    Time frame: From first dose of study drug to 24 months

  19. Plasma Sevasemten (EDG-5506) Concentrations at Sample Timepoints

    Values below the limit of quantitation (BLQ) of 0.500 ng/mL were treated as 0 before the first quantifiable concentration and as missing elsewhere. Single PK concentration was collected at each visit, except for Day 1. For treatment-naive participants, Day 1 was a serial collection at pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, and 24 hours post-dose. The last timepoint was on Day 2. The dose on Day 2 was administered only after the 24 hour timepoint. For treatment experienced participants, Day 1 was pre-dose only. Days 29 and 57 have window of +/- 3 days; Months 3-24 have window of +/- 5 days.

    Time frame: Pre-dose; 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, and 24 hours post-dose; 29 and 57 days post-dose; 3, 4, 6, 7, 8, 10, 12, 15, 18, 21, and 24 months post-dose.

07

Results

Posted Jun 24, 2025

Participant flow

Participant flow — Overall Study
MilestoneTreatment
Started12
Completed9
Not completed3
Withdrew: Withdrawal by subject3

Outcome measures

PrimaryPercentage of Participants Treated With Sevasemten Experiencing AEs

An AE is any untoward medical occurrence in a patient administered a medicinal product. The AE does not necessarily have to have a causal relationship with the study drug. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. The numerator of the percentage is the number of participants experiencing at least one AE after first dose of study drug up to 25 months.

Time frame:
From first dose of study drug to 25 months
Reported as:
Number · percentage of participants
Percentage of Participants Treated With Sevasemten Experiencing AEs
percentage of participantsTreatment
Percentage of Participants Treated With Sevasemten Experiencing AEs100
PrimaryFrequency of AEs in Those Treated With Sevasemten

An AE is any untoward medical occurrence in a patient administered a medicinal product. The AE does not necessarily have to have a causal relationship with the study drug. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. The endpoint is the cumulative total number of AEs occurring after first dose of study drug up to 25 months among participants who received at least one dose of study drug.

Time frame:
From first dose of study drug to 25 months
Reported as:
Number · Count of Events
Frequency of AEs in Those Treated With Sevasemten
Count of EventsTreatment
Frequency of AEs in Those Treated With Sevasemten95
PrimaryNumber of Participants Treated With Sevasemten With AEs by Maximum Severity

An AE is any untoward medical occurrence in a patient administered a medicinal product. The AE does not necessarily have to have a causal relationship with the study drug. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. The severity of an AE is graded, according to the study protocol definitions of AE severity/intensity, as "mild", "moderate" or "severe". Participants who reported multiple AEs are counted only once at the highest severity reported.

Time frame:
From first dose of study drug to 25 months
Reported as:
Count of participants · Participants
Number of Participants Treated With Sevasemten With AEs by Maximum Severity
ParticipantsTreatment
Mild10
Moderate2
Severe0
SecondaryPercentage of Participants Experiencing Treatment-Emergent Abnormal Clinical Chemistry Test Results

Treatment-emergent defined as any event that occurs after the start of study drug or was present at baseline and worsened after taking study drug. The numerator of the percentage is the number of participants experiencing at least one treatment-emergent abnormal clinical chemistry test result after first dose of study drug up to 25 months.

Time frame:
From first dose of study drug to 25 months
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Abnormal Clinical Chemistry Test Results
percentage of participantsTreatment
Percentage of Participants Experiencing Treatment-Emergent Abnormal Clinical Chemistry Test Results0
SecondaryPercentage of Participants Experiencing Treatment-Emergent Abnormal Hematology Test Results

Treatment-emergent defined as any event that occurs after the start of study drug or was present at baseline and worsened after taking study drug. The numerator of the percentage is the number of participants experiencing at least one treatment-emergent abnormal hematology test result after first dose of study drug up to 25 months.

Time frame:
From first dose of study drug to 25 months
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Abnormal Hematology Test Results
percentage of participantsTreatment
Percentage of Participants Experiencing Treatment-Emergent Abnormal Hematology Test Results0
SecondaryPercentage of Participants Experiencing Treatment-Emergent Abnormal Coagulation Test Results

Treatment-emergent defined as any event that occurs after the start of study drug or was present at baseline and worsened after taking study drug. The numerator of the percentage is the number of participants experiencing at least one treatment-emergent abnormal coagulation test result after first dose of study drug up to 25 months.

Time frame:
From first dose of study drug to 25 months
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Abnormal Coagulation Test Results
percentage of participantsTreatment
Percentage of Participants Experiencing Treatment-Emergent Abnormal Coagulation Test Results0
SecondaryPercentage of Participants Experiencing Treatment-Emergent Abnormal Urinalysis Test Results

Treatment-emergent defined as any event that occurs after the start of study drug or was present at baseline and worsened after taking study drug. The numerator of the percentage is the number of participants experiencing at least one treatment-emergent abnormal urinalysis test result after first dose of study drug up to 25 months.

Time frame:
From first dose of study drug to 25 months
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Abnormal Urinalysis Test Results
percentage of participantsTreatment
Percentage of Participants Experiencing Treatment-Emergent Abnormal Urinalysis Test Results0
SecondaryNumber of Participants With Clinically Significant Changes in Clinical Chemistry

Refer to Protocol for list of clinical chemistry tests that were performed. Clinically significant changes in clinical chemistry are defined as adverse events related to clinical chemistry tests or investigator identified results reported from first dose of study drug up to 24 months. Only clinically significant changes were counted.

Time frame:
From first dose of study drug to 24 months
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes in Clinical Chemistry
ParticipantsTreatment
Number of Participants With Clinically Significant Changes in Clinical Chemistry0
SecondaryNumber of Participants With Clinically Significant Changes in Hematology

Refer to Protocol for list of hematology tests that were performed. Clinically significant changes in hematology are defined as adverse events related to hematology tests or investigator identified results reported from first dose of study drug up to 24 months. Only clinically significant changes were counted.

Time frame:
From first dose of study drug to 24 months
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes in Hematology
ParticipantsTreatment
Number of Participants With Clinically Significant Changes in Hematology0
SecondaryNumber of Participants With Clinically Significant Changes in Coagulation

Refer to Protocol for list of coagulation tests that were performed. Clinically significant changes in coagulation are defined as adverse events related to coagulation tests or investigator identified results reported from first dose of study drug up to 24 months. Only clinically significant changes were counted.

Time frame:
From first dose of study drug to 24 months
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes in Coagulation
ParticipantsTreatment
Number of Participants With Clinically Significant Changes in Coagulation0
SecondaryNumber of Participants With Clinically Significant Changes in Urinalysis

Refer to Protocol for list of urinalysis tests that were performed. Clinically significant changes in urinalysis are defined as adverse events related to urinalysis tests or investigator identified results reported from first dose of study drug up to 24 months. Only clinically significant changes were counted.

Time frame:
From first dose of study drug to 24 months
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes in Urinalysis
ParticipantsTreatment
Number of Participants With Clinically Significant Changes in Urinalysis0
SecondaryNumber of Participants With Clinically Significant Changes in Vital Signs

Supine systolic and diastolic blood pressure, pulse rate, respiratory rate, and temperature were measured. Clinically significant changes in vital signs are defined as adverse events related to vital signs or investigator identified results reported from first dose of study drug up to 24 months. Only clinically significant changes were counted.

Time frame:
From first dose of study drug to 24 months
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes in Vital Signs
ParticipantsTreatment
Number of Participants With Clinically Significant Changes in Vital Signs0
SecondaryNumber of Participants With Clinically Significant Changes in Physical and Neurological Examinations

A physical examination included head, ears, eyes, nose, mouth, skin, heart and lung, lymph nodes, and gastrointestinal and musculoskeletal systems. A neurological examination was also conducted to include upper and lower limb tone, power, reflexes, and examination of cranial nerves II-XII (excluding ophthalmoscopy). Clinically significant changes in physical and neurological examinations are defined as adverse events related to physical and neurological examinations or investigator identified results reported from first dose of study drug up to 24 months. Only clinically significant changes were counted.

Time frame:
From first dose of study drug to 24 months
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes in Physical and Neurological Examinations
ParticipantsTreatment
Number of Participants With Clinically Significant Changes in Physical and Neurological Examinations0
SecondaryNumber of Participants With Clinically Significant Changes in ECG PR Interval

Triplicate 12-lead electrocardiogram (ECG) parameters were obtained using an ECG machine that automatically measured PR interval. Clinically significant changes in ECG PR interval are defined as adverse events related to ECG PR interval or investigator identified results reported from first dose of study drug up to 24 months. Only clinically significant changes were counted.

Time frame:
From first dose of study drug to 24 months
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes in ECG PR Interval
ParticipantsTreatment
Number of Participants With Clinically Significant Changes in ECG PR Interval0
SecondaryNumber of Participants With Clinically Significant Changes in ECG QRS Interval

Triplicate 12-lead electrocardiogram (ECG) parameters were obtained using an ECG machine that automatically measured QRS interval. Clinically significant changes in ECG QRS interval are defined as adverse events related to ECG QRS interval or investigator identified results reported from first dose of study drug up to 24 months. Only clinically significant changes were counted.

Time frame:
From first dose of study drug to 24 months
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes in ECG QRS Interval
ParticipantsTreatment
Number of Participants With Clinically Significant Changes in ECG QRS Interval0
SecondaryNumber of Participants With Clinically Significant Changes in ECG QT Interval

Triplicate 12-lead electrocardiogram (ECG) parameters were obtained using an ECG machine that automatically measured QT interval. Clinically significant changes in ECG QT interval are defined as adverse events related to ECG QT interval or investigator identified results reported from first dose of study drug up to 24 months. Only clinically significant changes were counted.

Time frame:
From first dose of study drug to 24 months
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes in ECG QT Interval
ParticipantsTreatment
Number of Participants With Clinically Significant Changes in ECG QT Interval0
SecondaryNumber of Participants With Clinically Significant Changes in ECG QTc Interval

Triplicate 12-lead electrocardiogram (ECG) parameters were obtained using an ECG machine that automatically measured QT corrected (QTc) Interval. QT corrected by Bazett's formula (QTcB) and QT corrected by Fridericia's formula (QTcF) were both recorded. Clinically significant changes in ECG QTc interval are defined as adverse events related to ECG QTc interval or investigator identified results reported from first dose of study drug up to 24 months. Only clinically significant changes were counted.

Time frame:
From first dose of study drug to 24 months
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes in ECG QTc Interval
ParticipantsTreatment
Number of Participants With Clinically Significant Changes in ECG QTc Interval0
SecondaryNumber of Participants With Clinically Significant Changes in Forced Vital Capacity (FVC)

Assessed by spirometry. Clinically significant changes in FVC are defined as adverse events related to FVC or investigator identified results reported from first dose of study drug up to 24 months. Only clinically significant changes were counted.

Time frame:
From first dose of study drug to 24 months
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes in Forced Vital Capacity (FVC)
ParticipantsTreatment
Number of Participants With Clinically Significant Changes in Forced Vital Capacity (FVC)0
SecondaryNumber of Participants With Clinically Significant Changes in Forced Expiratory Volume in 1 Second (FEV1)

Assessed by spirometry. Clinically significant changes in FEV1 are defined as adverse events related to FEV1 or investigator identified results reported from first dose of study drug up to 24 months. Only clinically significant changes were counted.

Time frame:
From first dose of study drug to 24 months
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes in Forced Expiratory Volume in 1 Second (FEV1)
ParticipantsTreatment
Number of Participants With Clinically Significant Changes in Forced Expiratory Volume in 1 Second (FEV1)0
SecondaryNumber of Participants With Clinically Significant Changes in Cardiac Function as Assessed by Echocardiogram

Echocardiographic examinations were performed by a qualified individual (sonographer) at the site to evaluate left-ventricular systolic and diastolic function, geometry, and mass, as well as left-atrial and right-ventricular function and geometry via two-dimensional, doppler, and/or speckle-tracking imaging techniques. Valvular competence, including presence or absence of regurgitation, was evaluated and quantified, while overall cardiac health was qualitatively evaluated (e.g., presence/absence of pericardiac effusion). Clinically significant changes in cardiac function are defined as adverse events related to cardiac function as assessed by echocardiogram or investigator identified results reported from first dose of study drug up to 24 months. Only clinically significant changes were counted.

Time frame:
From first dose of study drug to 24 months
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes in Cardiac Function as Assessed by Echocardiogram
ParticipantsTreatment
Number of Participants With Clinically Significant Changes in Cardiac Function as Assessed by Echocardiogram0
SecondaryNumber of Participants With Clinically Significant Changes in Columbia Suicide Severity Rating Scale (C-SSRS)

The C-SSRS is a questionnaire used for suicide assessment. The assessment includes "yes" or "no" responses for 6 questions. Questions 1-5 are related to suicidal ideation, including: 1=Wish to be Dead, 2=Non-specific Active Suicidal Thoughts, 3=Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act, 4=Active Suicidal Ideation with Some Intent to Act, without Specific Plan, 5=Active Suicidal Ideation with Specific Plan and Intent. Question 6 is related to suicidal behavior and asks about actual attempts. Numeric ratings were provided for severity of ideation (if present), from 1 to 5, with 5 being the most severe. For this study, clinically significant changes in C-SSRS are defined as responses of "yes" to suicidal ideation or suicidal behavior item as measured by C-SSRS or investigator identified results reported from first dose of study drug to 24 months.

Time frame:
From first dose of study drug to 24 months
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes in Columbia Suicide Severity Rating Scale (C-SSRS)
ParticipantsTreatment
Number of Participants With Clinically Significant Changes in Columbia Suicide Severity Rating Scale (C-SSRS)0
SecondaryPlasma Sevasemten (EDG-5506) Concentrations at Sample Timepoints

Values below the limit of quantitation (BLQ) of 0.500 ng/mL were treated as 0 before the first quantifiable concentration and as missing elsewhere. Single PK concentration was collected at each visit, except for Day 1. For treatment-naive participants, Day 1 was a serial collection at pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, and 24 hours post-dose. The last timepoint was on Day 2. The dose on Day 2 was administered only after the 24 hour timepoint. For treatment experienced participants, Day 1 was pre-dose only. Days 29 and 57 have window of +/- 3 days; Months 3-24 have window of +/- 5 days.

Time frame:
Pre-dose; 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, and 24 hours post-dose; 29 and 57 days post-dose; 3, 4, 6, 7, 8, 10, 12, 15, 18, 21, and 24 months post-dose.
Reported as:
Mean · ng/mL
Plasma Sevasemten (EDG-5506) Concentrations at Sample Timepoints
ng/mLTreatment
Pre-dose0 ± 0
0.25 hours3.671 ± 4.1099
0.5 hours23.19 ± 30.408
1 hour21.68 ± 15.091
1.5 hours22.57 ± 10.959
2 hours21.60 ± 18.013
3 hours12.63 ± 6.5033
4 hours8.899 ± 2.3685
6 hours6.536 ± 2.5716
24 hours4.000 ± 1.5452
29 days53.27 ± 20.607
57 days60.57 ± 26.389
3 months93.63 ± 38.939
4 months92.34 ± 34.940
6 months105.3 ± 40.764
7 months137.4 ± 52.673
8 months137.7 ± 55.542
10 months149.3 ± 69.139
12 months141.7 ± 60.399
15 months175.2 ± 58.905
18 months78.20 ± 34.885
21 months69.33 ± 26.315
24 months55.38 ± 29.536

Adverse events

Collected over From first dose of study drug to 25 months.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment0/12 (0%)0/12 (0%)12/12 (100%)
Most frequent other events
Showing 10 of 43
Most frequent other events
EventTreatment
COVID-19Infections and infestations5/12
FallInjury, poisoning and procedural complications4/12
DizzinessNervous system disorders4/12
ArthralgiaMusculoskeletal and connective tissue disorders4/12
InfluenzaInfections and infestations3/12
NasopharyngitisInfections and infestations3/12
Viral upper respiratory tract infectionInfections and infestations3/12
Procedural painInjury, poisoning and procedural complications3/12
HeadacheNervous system disorders3/12
SomnolenceNervous system disorders3/12

Baseline characteristics

Participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)Treatment
Mean32.9 ± 7.98
Sex: Female, Male
Sex: Female, Male(Participants)Treatment
Female0
Male12
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Treatment
Hispanic or Latino1
Not Hispanic or Latino11
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Treatment
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White12
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Treatment
United States12
Height
Height(cm)Treatment
Mean175.37 ± 6.747
Weight
Weight(kg)Treatment
Mean77.77 ± 10.563
08

Study locations

1 site
  • Rare Disease Research
    Atlanta, Georgia 30329, United States
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2021 to primary completion in Mar 2024, 26 months.

Results were first posted in Jun 2025, 1 year 3 months after primary completion.

Of 28 phase 1 interventional studies under Muscular Dystrophy, Duchenne, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 35. This study's 26 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2021
First posted
Dec 16, 2021
StartActual
Dec 28, 2021
Primary completionActual
Mar 1, 2024
CompletionActual
Mar 1, 2024
Results first posted
Jun 24, 2025
Last update
Jun 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05160415
Lead sponsor
Edgewise Therapeutics, Inc.
Collaborators
Medpace, Inc.
Responsible party
Sponsor
First posted
Dec 16, 2021
Start date
Dec 28, 2021
Primary completion
Mar 1, 2024
Completion
Mar 1, 2024
Results posted
Jun 24, 2025
Last update
Jun 24, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sevasemten

Start the discussion